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Introduction
Canakinumab is a high-affinity fully human monoclonal
antibody of the IgG1/k isotype, designed to bind and
functionally neutralize the bioactivity of IL-1b, which is
recognized as one of the principal pro-inflammatory cyto-
kines in cryopyrin associated periodic syndromes (CAPS).
Objectives
The objectives of the study were to describe the kinetics of
canakinumab and dynamics of binding IL-1b in CAPS
patients; to determine if these are different in 2- and
3-year-old children versus older children and adults; and
to explore the impact of CAPS phenotype (Muckle-Wells
Syndrome [MWS], Familial Cold Autoinflammatory
Syndrome [FCAS], Neonatal-Onset Multisystem Inflam-
matory Disease [NOMID]) on the kinetics of canakinumab
and dynamics of binding to IL-1b.
Methods
A pharmacokinetics (PK)-binding model was used to
describe the kinetic and binding parameters of canakinu-
mab and IL-1b in CAPS patients, and in other populations
relative to CAPS. The subgroup of 7 CAPS patients who
were 2 and 3 years of age at baseline was also compared to
the overall CAPS population.
Results
The 7 CAPS patients did not show any difference in terms
of PK. However, they showed a higher IL-1b turnover
including IL-1b clearance and production. IL-1b levels
were linked with the severity of the CAPS phenotype.
In the pediatric population, MWS and especially
NOMID patients had higher concentrations of the inert
canakinumab/IL-1b complexes after administration of
canakinumab, indicating more cytokine in the body to be
captured.
Conclusion
Correlation with clinical responses suggested that these
increased levels of IL-1b may explain why younger and
NOMID phenotype patients require higher doses or
escalation to higher doses.
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